Genfit SA

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

23 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2023 Financial Information

11 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

09 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of Extra-Financial Performance Report 2022

27 Apr 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

19 Apr 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

18 Apr 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

13 Apr 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2022

28 Feb 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

30 Jan 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces 2023 Financial Calendar

24 Jan 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT to Participate in Upcoming Investor Conferences

05 Jan 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

17 Nov 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2022 Financial Information

10 Nov 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®

25 Oct 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

29 Sep 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

28 Sep 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

19 Sep 2022 00:30:00 By Nasdaq GlobeNewswire

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

13 Sep 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

08 Jul 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: May 25, 2022 Combined Shareholders Meeting results

25 May 2022 15:10:00 By Nasdaq GlobeNewswire